Shanghai XBH Biotechnology

Shanghai XBH Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing next-generation small molecule drugs for autoimmune and inflammatory diseases. The company focuses on high-selectivity inhibitors of the Janus kinase (JAK) family, particularly targeting the TYK2 and JAK1 pathways to minimize off-target side effects associated with first-generation inhibitors. Its lead candidate, XBH-002, is a potent and selective TYK2 JH2 domain inhibitor currently being evaluated in clinical trials for psoriasis and other immune-mediated conditions. Founded by industry veterans with extensive experience in medicinal chemistry, XBH Biotechnology aims to address significant unmet medical needs in the global immunology market. The company's R&D strategy emphasizes precision targeting to improve the therapeutic window of oral treatments for chronic inflammatory disorders.